Purpose Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations. Methods A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone’s cardiovascular and renal effects. Three RCTs were included—FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF—encompassing 19,027 participants. Primary outcomes included cardiovascular death, HF hospitalization, and renal failure. Secondary outcomes focused on safety and adverse events like acute kidney injury and hyperkalemia. Meta-analyses were performed using hazard ratios (HR), confidence intervals (CI), and Relative Risk (RR). Results Finerenone was associated with a 20% reduction in HF hospitalization risk (HR 0.80, 95% CI: 0.72–0.90) and a 14% reduction in all-cause mortality (RR 0.86, 95% CI: 0.77–0.97). Finerenone did not significantly reduce cardiovascular death (HR 0.91, 95% CI: 0.82–1.01, p = 0.06). Renal failure rates were similar between Finerenone and placebo (RR 1.05, 95% CI: 0.65–1.68). Hyperkalemia incidence was significantly higher with Finerenone, with a RR of 2.31 (95% CI: 1.98–2.69). Conclusion This meta-analysis shows that Finerenone significantly reduces HF hospitalizations and all-cause mortality in patients with chronic kidney disease and heart failure. Further studies are needed to clarify its effects on cardiovascular death and renal failure.
Social Determinants of Health (SDOH) like education, economic stability, social context, neighborhood environment, and healthcare access are increasingly recognized as major drivers of persistent health disparities, particularly among minority populations. Over the past year, studies have demonstrated and quantified the impact that certain SDOH have on uncontrolled blood pressure in Black and Hispanic adults compared to white adults. This underscores the need to view chronic diseases through a SDOH lens and implement multilevel interventions targeting these underlying social factors to achieve health equity. The ShopTalk initiative, based in Lakeland, Florida, represents a promising community-based approach to addressing SDOH and health disparities. It conducts health outreach in barbershops and hair salons - trusted community hubs where meaningful dialogues occur. Key components include providing health education materials, offering screenings, and facilitating physician connections, all at no cost. By leveraging these culturallyrelevant spaces, ShopTalk simultaneously targets multiple SDOH domains like health literacy, economic barriers, neighborhood familiarity, and healthcare engagement. This builds upon the pioneering work of leaders like Dr. Elijah Saunders and Dr. Ronald Victor, who previously engaged social hubs to successfully raise hypertension awareness among underserved populations. As highlighted by Healthy People 2030's emphasis on SDOH, widespread implementation of such culturally-tailored community outreach shows potential for finally reducing longstanding disparities. Specific outcome measures are planned to optimize ShopTalk, with the goal of extracting generalizable insights to guide similar initiatives nationwide.
27 May 2024 in Archives des Maladies du Coeur et des Vaisseaux - Pratique